Molecular Formula | C18H21Cl2N7O2
|
Molar Mass | 438.31104 |
Solubility | DMSO: ≥ 32 mg/mL |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vitro study | In preclinical studies, LY2606368 was found to induce DNA damage. Treatment of cells with LY2606368 will result in the rapid appearance of TUNEL and pH2AXy positive double-stranded DNA breaks in cells in S phase. In HeLa cells with p53 deficiency, LY2606368 effectively abolished the G2-M checkpoint of doxorubicin activation with an EC50 of 9 nM. LY2606368 can widely play an anti-proliferative role in a variety of cells, in most sensitive cell lines, IC50s < 50 nM; Only a few cell lines are resistant to LY2606368, IC50s > 1000 nM. LY2606368 requires CDC25A and CDK2 to cause DNA damage. |
In vivo study | In the tumor xenograft model, LY2606368 can effectively inhibit tumor growth and exert anti-tumor activity whether administered alone or in combination with other drugs. In the SKOV3 ovarian cancer model, LY2606368 inhibited the growth of the primary tumor and significantly reduced the metastasis rate and ascites accumulation. In the SW1990 Orthotopic Pancreatic cancer model, LY2606368 inhibited primary tumor growth by 92%, preventing metastasis to lymph node tuberculosis, spleen, and intestinal tract. |